TransMedics [TMDX] vs Globus Medical [GMED] Detailed Stock Comparison
TransMedics
NASDAQ
Loading...
Globus Medical
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: TransMedics wins in 3 metrics, Globus Medical wins in 16 metrics, with 0 ties. Globus Medical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | TransMedics | Globus Medical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 59.92 | 23.71 | Globus Medical |
| Price-to-Book Ratio | 12.76 | 1.92 | Globus Medical |
| Debt-to-Equity Ratio | 163.10 | 2.83 | Globus Medical |
| PEG Ratio | 0.34 | 0.04 | Globus Medical |
| EV/EBITDA | 42.88 | 11.09 | Globus Medical |
| Profit Margin (TTM) | 13.49% | 13.58% | Globus Medical |
| Operating Margin (TTM) | 23.24% | 17.33% | TransMedics |
| EBITDA Margin (TTM) | 23.24% | 17.33% | TransMedics |
| Return on Equity | 28.21% | 8.62% | TransMedics |
| Return on Assets (TTM) | 5.80% | 5.82% | Globus Medical |
| Free Cash Flow (TTM) | $-80.94M | $405.21M | Globus Medical |
| 1-Year Return | -32.36% | -16.03% | Globus Medical |
| Price-to-Sales Ratio (TTM) | 7.65 | 3.15 | Globus Medical |
| Enterprise Value | $4.30B | $8.15B | Globus Medical |
| EV/Revenue Ratio | 8.09 | 3.10 | Globus Medical |
| Gross Profit Margin (TTM) | 61.38% | 66.62% | Globus Medical |
| Revenue per Share (TTM) | $16 | $19 | Globus Medical |
| Earnings per Share (Diluted) | $1.99 | $2.58 | Globus Medical |
| Beta (Stock Volatility) | 2.09 | 1.20 | Globus Medical |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
TransMedics vs Globus Medical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| TransMedics | -2.52% | -8.42% | 14.67% | -2.06% | 65.13% | 78.66% |
| Globus Medical | -0.38% | 0.80% | 16.59% | 2.06% | -24.64% | -26.07% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| TransMedics | -32.36% | 127.30% | 568.22% | 379.07% | 379.07% | 379.07% |
| Globus Medical | -16.03% | 0.27% | 7.14% | 144.44% | 348.15% | 348.15% |
Performance & Financial Health Analysis: TransMedics vs Globus Medical
| Metric | TMDX | GMED |
|---|---|---|
| Market Information | ||
| Market Cap | $4.07B | $8.26B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 866,924 | 1,846,380 |
| 90 Day Avg. Volume | 1,217,355 | 1,622,753 |
| Last Close | $118.81 | $60.50 |
| 52 Week Range | $55.00 - $177.37 | $51.79 - $94.93 |
| % from 52W High | -33.02% | -36.27% |
| All-Time High | $177.37 (Aug 19, 2024) | $94.93 (Jan 27, 2025) |
| % from All-Time High | -33.02% | -36.27% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.38% | 0.18% |
| Quarterly Earnings Growth | 1.86% | 5.39% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.14% |
| Operating Margin (TTM) | 0.23% | 0.17% |
| Return on Equity (TTM) | 0.28% | 0.09% |
| Debt to Equity (MRQ) | 163.10 | 2.83 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $9.35 | $31.81 |
| Cash per Share (MRQ) | $11.75 | $1.70 |
| Operating Cash Flow (TTM) | $115.27M | $669.16M |
| Levered Free Cash Flow (TTM) | $-7,754,500 | $456.11M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: TransMedics vs Globus Medical
| Metric | TMDX | GMED |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 59.92 | 23.71 |
| Forward P/E | 72.27 | 17.89 |
| PEG Ratio | 0.34 | 0.04 |
| Price to Sales (TTM) | 7.65 | 3.15 |
| Price to Book (MRQ) | 12.76 | 1.92 |
| Market Capitalization | ||
| Market Capitalization | $4.07B | $8.26B |
| Enterprise Value | $4.30B | $8.15B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.09 | 3.10 |
| Enterprise to EBITDA | 42.88 | 11.09 |
| Risk & Other Metrics | ||
| Beta | 2.09 | 1.20 |
| Book Value per Share (MRQ) | $9.35 | $31.81 |
Financial Statements Comparison: TransMedics vs Globus Medical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TMDX | GMED |
|---|---|---|
| Revenue/Sales | $143.54M | $598.12M |
| Cost of Goods Sold | $55.31M | $195.40M |
| Gross Profit | $88.23M | $402.72M |
| Research & Development | $17.16M | $33.06M |
| Operating Income (EBIT) | $27.44M | $98.06M |
| EBITDA | $36.27M | $160.92M |
| Pre-Tax Income | $26.68M | $103.67M |
| Income Tax | $994,000 | $28.21M |
| Net Income (Profit) | $25.68M | $75.46M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TMDX | GMED |
|---|---|---|
| Cash & Equivalents | $310.14M | $461.27M |
| Total Current Assets | $505.92M | $1.71B |
| Total Current Liabilities | $55.60M | $384.70M |
| Long-Term Debt | $515.62M | $81.69M |
| Total Shareholders Equity | $266.31M | $4.09B |
| Retained Earnings | $-442.56M | $1.04B |
| Property, Plant & Equipment | $40.54M | $1.06B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TMDX | GMED |
|---|---|---|
| Operating Cash Flow | $354,000 | $193.84M |
| Capital Expenditures | $-27.04M | $-36.10M |
| Free Cash Flow | $-29.89M | $136.20M |
| Debt Repayment | N/A | $-449.99M |
| Common Stock Repurchase | N/A | $-190.45M |
Short Interest & Institutional Ownership Analysis
| Metric | TMDX | GMED |
|---|---|---|
| Shares Short | 7.67M | 4.78M |
| Short Ratio | 6.69 | 2.94 |
| Short % of Float | 0.39% | 0.05% |
| Average Daily Volume (10 Day) | 866,924 | 1,846,380 |
| Average Daily Volume (90 Day) | 1,217,355 | 1,622,753 |
| Shares Outstanding | 33.62M | 137.42M |
| Float Shares | 32.96M | 111.73M |
| % Held by Insiders | 0.03% | 0.01% |
| % Held by Institutions | 1.13% | 1.05% |
Dividend Analysis & Yield Comparison: TransMedics vs Globus Medical
| Metric | TMDX | GMED |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |